Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Agus

Showing results (31-40 of 71) with videos related to

Pageof 8
Sort By:
Clinical Genitourinary Cancer|August 23, 2017
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)Mitchell E Gross, Tanya B Dorff, David I Quinn, et al.
Psycho-Oncology|March 17, 2012
Body image predicts quality of life in men with prostate cancerMegan Taylor-Ford, Beth E Meyerowitz, Lina M D'Orazio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancerWilliam D Fox, Brian Higgins, Krista M Maiese, et al.
Molecular Pharmaceutics|October 15, 2011
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerShannon M Mumenthaler, Jasmine Foo, Kevin Leder, et al.
Nature Communications|November 17, 2020
Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stainsNikhil Naik, Ali Madani, Andre Esteva, et al.
The Prostate|September 16, 2004
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenograftsAnna V Galkin, Lynne Mullen, William D Fox, et al.
BMC Systems Biology|September 23, 2016
Quantifying differences in cell line population dynamics using CellPDEdwin F Juarez, Roy Lau, Samuel H Friedman, et al.
Investigational New Drugs|December 18, 2012
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsMichael S Gordon, David S Mendelson, Mitchell Gross, et al.
Cancer Informatics|August 6, 2015
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer CellsShannon M Mumenthaler, Jasmine Foo, Nathan C Choi, et al.
Prostate Cancer and Prostatic Diseases|March 4, 2020
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancerMitchell E Gross, David B Agus, Tanya B Dorff, et al.
Pageof 8

Showing results (31-40 of 71) with videos related to

Sort By:
Pageof 8
Clinical Genitourinary Cancer|August 23, 2017
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)Mitchell E Gross, Tanya B Dorff, David I Quinn, et al.
Psycho-Oncology|March 17, 2012
Body image predicts quality of life in men with prostate cancerMegan Taylor-Ford, Beth E Meyerowitz, Lina M D'Orazio, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancerWilliam D Fox, Brian Higgins, Krista M Maiese, et al.
Molecular Pharmaceutics|October 15, 2011
Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerShannon M Mumenthaler, Jasmine Foo, Kevin Leder, et al.
Nature Communications|November 17, 2020
Deep learning-enabled breast cancer hormonal receptor status determination from base-level H&E stainsNikhil Naik, Ali Madani, Andre Esteva, et al.
The Prostate|September 16, 2004
CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenograftsAnna V Galkin, Lynne Mullen, William D Fox, et al.
BMC Systems Biology|September 23, 2016
Quantifying differences in cell line population dynamics using CellPDEdwin F Juarez, Roy Lau, Samuel H Friedman, et al.
Investigational New Drugs|December 18, 2012
A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsMichael S Gordon, David S Mendelson, Mitchell Gross, et al.
Cancer Informatics|August 6, 2015
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer CellsShannon M Mumenthaler, Jasmine Foo, Nathan C Choi, et al.
Prostate Cancer and Prostatic Diseases|March 4, 2020
Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancerMitchell E Gross, David B Agus, Tanya B Dorff, et al.
Pageof 8